

Australasian Bone Marrow Transplant Recipient Registry

Annual Data Summary 2017

Contents

| | |
|---|-----------|
| Introduction | 1 |
| Registry data 1992-2017 | 2 |
| Transplant activity | 2 |
| Autologous and allogeneic transplants | 2 |
| Stem cell source for autologous transplants | 3 |
| Stem cell source for allogeneic transplants | 3 |
| Indications for autologous transplant | 4 |
| Indications for allogeneic transplant | 4 |
| Allogeneic transplants for myeloma | 5 |
| Allogeneic transplants for Hodgkin lymphoma | 5 |
| Donor source for allogeneic transplants | 6 |
| Transplant activity by age group | 6 |
| Transplant activity 2017 | 7 |
| Haematopoietic cell transplant activity summary | 7 |
| Transplant activity by state and country | 8 |
| Transplant activity 2017 by state / country and hospital type | 9 |
| Haematopoietic cell transplants by type | 10 |
| Outpatient procedures | 10 |
| Transplant and recipient characteristics | 11 |
| Transplant recipients by age group | 11 |
| Stem cell source for haematopoietic cell transplants | 12 |
| Stem cell source by donor type | 12 |
| HLA compatibility for allogeneic transplants | 13 |
| Number of infusions for staged autologous transplants | 13 |
| Conditioning agents for autologous transplants | 14 |
| Conditioning intensity for allogeneic transplants | 14 |
| Conditioning agents for allogeneic transplants | 15 |
| Recipients aged 0-15 | 15 |
| Recipients aged 16+ | 15 |
| ATG and Campath by donor relation | 16 |
| Graft vs host disease prophylaxis by donor relation | 16 |
| Indication for transplant | 17 |
| !Unexpected End of Formula | |
| Recipients aged 0-15: transplant indications | 18 |
| Acute leukaemia by disease stage, all ages (allogeneic transplants) | 18 |
| Recipients aged 16+: autologous transplants | 19 |
| Recipients aged 16+: allogeneic transplants | 20 |
| Unrelated donor transplants | 21 |
| Stem cell source - recipients aged 0-15 | 21 |
| Stem cell source - recipients aged 16+ | 21 |
| Donor country for Australian unrelated donor transplants | 22 |
| Australian peripheral blood and marrow transplants | 22 |
| Australian cord blood transplants | 22 |

| | |
|---|-----------|
| Donor country - marrow and peripheral blood | 23 |
| Donor country - cord blood | 23 |
| Adverse events in the first 100 days..... | 24 |
| Performance status 1 year post transplant (Lansky/Karnofsky)..... | 24 |
| Outcomes in the first year post transplant | 25 |
| Recipients aged 0-15..... | 25 |
| Neutrophil engraftment 2017 – matched sibling donor..... | 25 |
| Neutrophil engraftment 2017 – unrelated donor..... | 25 |
| Platelet engraftment 2017 – matched sibling donor | 26 |
| Platelet engraftment 2017 – unrelated donor | 26 |
| Acute GVHD 2017 all grades – matched sibling donor | 27 |
| Acute GVHD 2017 all grades – unrelated donor | 27 |
| Acute GVHD 2017 grade II and above – matched sibling donor | 28 |
| Acute GVHD 2017 grade II and above – unrelated donor | 28 |
| Chronic GVHD 2001-16 – matched sibling donor | 29 |
| Chronic GVHD 2001-16 – other related donor | 29 |
| Chronic GVHD 2001-16 – unrelated donor | 30 |
| One year survival 2001-2016 | 30 |
| Recipients aged 16+ | 31 |
| Neutrophil engraftment 2017 – matched sibling donor..... | 31 |
| Neutrophil engraftment 2017 – unrelated donor..... | 31 |
| Platelet engraftment 2017 – matched sibling donor | 32 |
| Platelet engraftment 2017 – unrelated donor | 32 |
| Neutrophil engraftment 2017 - autologous for lymphoma (BEAM conditioning) | 33 |
| Neutrophil engraftment 2017 – autologous for myeloma (Melphalan conditioning) .. | 33 |
| Platelet engraftment 2017 – autologous for lymphoma (BEAM conditioning)..... | 34 |
| Platelet engraftment 2017 – autologous for myeloma (Melphalan conditioning) | 34 |
| Acute GVHD 2017 all grades - matched sibling donor..... | 35 |
| Acute GVHD 2017 all grades – unrelated donor | 35 |
| Acute GVHD 2017 grade II and above - matched sibling donor | 36 |
| Acute GVHD 2017 grade II and above – unrelated donor | 36 |
| Chronic GVHD 2001-16 – matched sibling donor | 37 |
| Chronic GVHD 2001-16 – other related donor | 37 |
| Chronic GVHD 2001-16 – unrelated donor | 38 |
| One year survival 2001-2016 | 38 |
| Ten-year survival - first transplants 2001-2016 | 39 |
| Recipients aged 0-15..... | 39 |
| Acute lymphoblastic leukaemia - HLA identical sibling donor | 39 |
| Acute lymphoblastic leukaemia - unrelated donor..... | 39 |
| Acute lymphoblastic leukaemia - unrelated cord vs other related donor..... | 40 |
| Acute myeloid leukaemia - HLA identical sibling donor | 40 |
| Immune deficiencies | 41 |
| Aplastic anaemia | 41 |
| Neuroblastoma | 42 |
| Medulloblastoma..... | 42 |
| Recipients aged 16+ | 43 |
| Acute myeloid leukaemia - HLA identical sibling donor | 43 |
| Acute myeloid leukaemia - unrelated donor | 43 |
| Acute myeloid leukaemia - unrelated cord vs other related donor | 44 |

| | |
|---|-----------|
| Acute lymphoblastic leukaemia - HLA identical sibling donor | 44 |
| Acute lymphoblastic leukaemia - unrelated donor..... | 45 |
| Acute lymphoblastic leukaemia - unrelated cord vs other related donor..... | 45 |
| Chronic myeloid leukaemia - HLA identical sibling donor | 46 |
| Chronic myeloid leukaemia - unrelated donor | 46 |
| Myelodysplasia - HLA-identical sibling donor | 47 |
| Myelodysplasia - unrelated donor..... | 47 |
| Myeloma | 48 |
| Myeloma - allogeneic..... | 48 |
| Hodgkin lymphoma - autologous | 49 |
| Hodgkin lymphoma – allogeneic..... | 49 |
| Non-Hodgkin lymphoma - autologous | 50 |
| Non-Hodgkin lymphoma – allogeneic..... | 50 |
| Primary amyloidosis | 51 |
| Testicular cancer | 51 |
| Aplastic anaemia | 52 |
| Ewing sarcoma - adult and paediatric autologous..... | 52 |
| Transplant related mortality | 53 |
| 100 day and 1 year TRM 2012-2016..... | 53 |
| TRM trends: recipients aged 0-15 | 53 |
| TRM trends: recipients aged 16+ | 54 |
| Cause of death post transplant | 55 |
| Primary cause of death post autologous transplant | 55 |
| Recipients aged 0-15..... | 55 |
| Recipients aged 16+ | 56 |
| Contributing causes of TRM in the first year post autologous transplant..... | 56 |
| Primary cause of death post allogeneic transplant - first year..... | 57 |
| Recipients aged 0-15..... | 57 |
| Contributing causes of TRM in the first year post allogeneic transplant | 57 |
| Recipients aged 16+ | 58 |
| Contributing causes of TRM in the first year post allogeneic transplant | 58 |
| Primary cause of death post allogeneic transplant - second year..... | 59 |
| Recipients aged 0-15..... | 59 |
| Recipients aged 16+ | 60 |
| Contributing centres..... | 61 |
| Australia | 61 |
| New Zealand..... | 61 |
| Publications..... | 62 |